April 18th 2024
Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Age, Gender Among Factors Associated With Depression and Fatigue After HCT
February 11th 2016A number of clinical and sociodemographic factors, including age and gender, were found to be independently associated with fatigue and depression among cancer patients who were treated with hematopoietic cell transplantation.
MTSS1 Protein May Act As Tumor Suppressor, Downregulated in CML
January 29th 2016Laboratory studies of mice and human cells found that a protein called Metastasis suppressor 1 (Mtss1) is downregulated in hematopoietic and progenitor cells when chronic myeloid leukemia is present. Mtss1 levels are restored when complete remission is achieved, suggesting the pathway might represent a new therapeutic target.
Pioglitazone, Other TZDs May Add Benefit to TKI Therapy in CML
January 11th 2016A laboratory study showed that peroxisome proliferator-activated receptor gamma agonists such as pioglitazone could help treat chronic myeloid leukemia patients who are resistant or otherwise unresponsive to treatment with tyrosine kinase inhibitors.
Real-Time Classification Finds High-Risk ALL With Favorable Outcomes
December 8th 2015Real-time classification can identify a previously unrecognized subset of high-risk patients with childhood B-cell acute lymphoblastic leukemia who have excellent chances for cure without further intensification of treatment.